PMID- 36178283
OWN - NLM
STAT- MEDLINE
DCOM- 20230118
LR  - 20230926
IS  - 1309-5730 (Electronic)
IS  - 1018-5615 (Print)
IS  - 1018-5615 (Linking)
VI  - 39
IP  - 1
DP  - 2023
TI  - cERBB-2/Her-2 Neu Overexpression and Prognostic Significance in Uterine 
      Carcinosarcoma.
PG  - 55-63
LID - 10.5146/tjpath.2022.01588 [doi]
AB  - OBJECTIVE: There is not enough data in the literature regarding Her-2 
      overexpression in uterine carcinosarcomas or its association with the prognosis. 
      The aim of this study was to determine the Her-2 overexpression rate in uterine 
      carcinosarcoma and to evaluate its relationship with the prognosis. MATERIAL AND 
      METHOD: Her-2 protein and gene status were evaluated by immunohistochemistry 
      (IHC) and fluorescence in situ hybridization (FISH), respectively, in 
      hysterectomy specimens from 51 patients with uterine carcinosarcoma. RESULTS: 
      Her-2 protein expression in the epithelial component was negative in 42 patients 
      (score 0 in 33 cases, score (+1) in 9 cases), score (+2) in 7 patients and score 
      (+3) in 2 patients. None of the patients had Her-2 protein expression within the 
      sarcomatous component of the tumors. Her-2 gene was not amplified in epithelial 
      or mesenchymal tumor areas according to the FISH method. There was no difference 
      between the Her-2 overexpression negative and positive groups in terms of 
      disease-free survival (DFS) and overall survival (OS). Her-2 overexpression was 
      significantly higher in tumors of patients diagnosed at 65 years or older 
      (p=0.046). CONCLUSION: In our study, no relationship could be shown between Her-2 
      overexpression and prognosis in uterine carcinosarcoma. More comprehensive 
      studies are needed to illustrate the relationship between Her-2 overexpression 
      and carcinosarcoma prognosis.
FAU - Semiz, Huseyin Salih
AU  - Semiz HS
AD  - Department of Medical Oncology, Dokuz Eylul University Institute of Oncology, 
      IZMIR, TURKEY.
FAU - Pala, Emel Ebru
AU  - Pala EE
FAU - Can, Behzat
AU  - Can B
FAU - Atag, Elif
AU  - Atag E
FAU - Gungor, Hatice
AU  - Gungor H
FAU - Sanci, Muzaffer
AU  - Sanci M
LA  - eng
PT  - Journal Article
TT  - cERBB-2/Her-2 Neu Overexpression and Prognostic Significance in Uterine 
      Carcinosarcoma.
PL  - Turkey
TA  - Turk Patoloji Derg
JT  - Turk patoloji dergisi
JID - 9440471
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Female
MH  - Humans
MH  - Prognosis
MH  - In Situ Hybridization, Fluorescence
MH  - Receptor, ErbB-2/genetics
MH  - Immunohistochemistry
MH  - *Carcinosarcoma/genetics/metabolism/pathology
MH  - *Uterine Neoplasms/genetics/pathology
MH  - Gene Amplification
PMC - PMC10518127
COIS- I certify that all of my affiliations with or without financial involvement, 
      within the past 5 years and foreseeable future, and any organization or entity 
      with a financial interest in or financial conflict with the subject matter or 
      materials discussed in the manuscript are completely disclosed (e.g., employment, 
      consultancies, honoraria, stock ownership or options, expert testimony, grants or 
      patents received or pending, and royalties).
EDAT- 2022/10/01 06:00
MHDA- 2023/01/19 06:00
PMCR- 2023/01/15
CRDT- 2022/09/30 08:53
PHST- 2022/10/01 06:00 [pubmed]
PHST- 2023/01/19 06:00 [medline]
PHST- 2022/09/30 08:53 [entrez]
PHST- 2023/01/15 00:00 [pmc-release]
AID - 10.5146/tjpath.2022.01588 [doi]
PST - ppublish
SO  - Turk Patoloji Derg. 2023;39(1):55-63. doi: 10.5146/tjpath.2022.01588.